Supplementary Figure 1. Lnc-BMP1-1 was over-expressed in lung cancer cells. (A) The represented fluorescence microscope pictures of A549, PC9 and GLC82 cells with Lnc-BMP1-1 over-expression, and the corresponding bar graph of (B) A549-BMP vs A549-NC cells; (C) PC9-BMP vs PC9-NC cells; (D) GLC82-BMP vs. GLC82-NC cells. Data are represented as means±SD. *P<0.05, **P<0.01.
Supplementary Figure 2. The expression of DNMTs with 5-AzaC and TSA treatment, the methylation status of Cav-1 promoter in A549-BMP vs. A549-NC cells, and the drug sensitivity trial of DDP. (A) The expression of DNMT3b mRNA of A549 cells with 5-AzaC or TSA treatment; (B) The expression of DNMT1 mRNA of A549 cells with 5-AzaC or TSA treatment; (C) There’s no significant difference between A549-BMP and A549-NC cells in the DNA methylation status of Cav-1 promoter; (D) There’s no significant difference between A549-BMP and A549-NC cells in the cell viability under the same treatment of DDP. Data are represented as means ± SD.